Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca’s Japan COVID-19 Vaccine Trial Ongoing after Death Reported in Brazil
October 23, 2020
- Kyowa Kirin Delivers Positive PIIb Data for Parkinson’s Med KW-6356
October 22, 2020
- Aducanumab Filed in Europe: Biogen/Eisai
October 22, 2020
- Chugai Licenses Antibody Engineering Tech to Novo
October 22, 2020
- GSK Sets Up Oncology Biz Unit in Japan; Multiple Late-Stage Assets in Pipeline
October 22, 2020
- Pfizer, BioNTech Begin Japan PI/II Study for COVID-19 Vaccine
October 21, 2020
- Drug Promotions Collectively Down in August: Intage
October 21, 2020
- Astellas Wins FDA’s Fast-Track Tag for Primary Mitochondrial Myopathies Drug
October 21, 2020
- Sawai to Launch Zagallo Generic on Nov. 6
October 20, 2020
- Pfizer Starts Promotion for 4 Authorized Generics, Including Lyrica AG
October 20, 2020
- LEO Pharma’s Atopic Dermatitis Program Lags as PMDA Requests Japanese Data, but Growth Goal Intact
October 20, 2020
- Fujifilm Eyes Avigan Use in Mild and Severe COVID-19 Cases: Exec
October 19, 2020
- Chinese Regulators Accept Eisai’s Fycompa for Monotherapy, Additional Pediatric Use
October 19, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
- JPWA Raided Too over Big 4 Wholesalers’ Bid-Rigging Scandal
October 16, 2020
- Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Evaluating Vaccine Efficacy Will Be a Challenge for COVID-19 Vaccine Development in Japan: Developers
October 16, 2020
- Chugai Files 1st Oral SMA Treatment in Japan
October 16, 2020
- Otsuka Misses Primary Goal in PIII Guadecitabine Trials
October 16, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…